oncliveMay 141 min read

Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian Cancer

The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

oncliveMay 141 min read

The addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.

source

Reporting by onclive. The original article may no longer be reachable at its published URL.